natgillin/translations-raw huggingface dataset:
Fax number: +49 7621 1693 474 
Faks: +49 7621 1693 474
((Back Cover)) 
((Zadnja stran ovojnine))
What Deferiprone Lipomed is and what it is used for 2. 
Kaj je zdravilo Deferiprone Lipomed in za kaj ga uporabljamo
The most serious side effect of Deferiprone Lipomed is a very low white blood cell (neutrophil) count. 
Najresnejši neželeni učinek jemanja zdravila Deferiprone Lipomed je zelo nizka koncentracija belih krvnih celic (nevtrofilcev).
- Provided in the folding box, you will find a patient/carer reminder card. You should complete and read the card carefully and carry it with you. 
Kartico izpolnite, natančno preberite in nosite s sabo.
The most serious side effect that may occur while taking Deferiprone Lipomed is a very low white blood cell (neutrophil) count. 
Najresnejši neželeni učinek, ki se lahko pojavi ob jemanju zdravila Deferiprone Lipomed, je zelo nizka koncentracija belih krvničk (nevtrofilcev) v krvi.
Croscarmellose sodium Silica, colloidal anhydrous Microcrystalline cellulose Magnesium stearate 
Jedro tablete hipromeloza premreženi natrijev karmelozat brezvodni koloidni silicijev dioksid mikrokristalna celuloza magnezijev stearat
Each 500 mg film-coated tablet contains 500 mg deferiprone. 
Vsaka 500 mg filmsko obložena tableta vsebuje 500 mg deferiprona.
Deferiprone Lipomed will be most effective if you do not miss any doses. 
Če ste pozabili vzeti zdravilo Deferiprone Lipomed Zdravilo Deferiprone Lipomed bo najbolj učinkovito, če ne boste pozabili vzeti niti enega odmerka.
Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. 
Monoterapija z zdravilom Deferiprone Lipomed je indicirana za zdravljenje preobremenjenosti z železom pri bolnikih s talasemijo major, če je trenutna kelacijska terapija kontraindicirana ali nezadostna.
Do not take medicines known to cause neutropenia or agranulocytosis (see “Do not take Deferiprone Lipomed”). 
Druga zdravila in zdravilo Deferiprone Lipomed Ne jemljite zdravil, za katera je znano, da povzročajo nevtropenijo ali agranulocitozo (glejte poglavje »Ne jemljite zdravila Deferiprone Lipomed«).
Driving and using machines Not relevant. 
Vpliv na sposobnost upravljanja vozil in strojev Podatek ni potreben.
Deferiprone is usually given as 25 mg/kg body weight, orally, three times a day for a total daily dose of 75 mg/kg body weight. 
Deferipron se najpogosteje predpisuje v odmerku 25 mg/kg telesne mase, peroralno, trikrat na dan, največji skupni dnevni odmerek je 75 mg/kg telesne mase.
An open-label, non-randomized, parallel group clinical study was conducted to evaluate the effect of impaired renal function on the safety, tolerability, and pharmacokinetics of a single 33 mg/kg oral dose of deferiprone. 
Opravljeno je bilo odprto, nerandomizirano klinično preskušanje z vzporednima skupinama, da bi ocenili učinek okvarjenega delovanja ledvic na varnost, prenašanje in farmakokinetiko enkratnega peroralnega odmerka deferiprona 33 mg/kg.
Studies in animals have shown reproductive toxicity (see section 5.3). 
Študije na živalih so pokazale vpliv deferiprona na sposobnost razmnoževanja (glejte poglavje 5.3).
Based on the results of this study, no adjustment of the deferiprone dosage regimen is required in patients with impaired renal function. 
Na podlagi rezultatov te študije pri bolnikih z okvarjenim delovanjem ledvic prilagoditev režima odmerjanja deferiprona ni potrebna.
What Deferiprone Lipomed looks like and contents of the pack Deferiprone Lipomed 500 mg film-coated tablets are white to off-white, glossy surface, oval filmcoated tablets. 
Izgled zdravila Deferiprone Lipomed in vsebina pakiranja Deferiprone Lipomed 500 mg filmsko obložene tablete so bele do sivobele gladke ovalne filmsko obložene tablete.
• Due to the unknown mechanism of deferiprone-induced neutropenia, patients must not take medicinal products known to be associated with neutropenia or those that can cause agranulocytosis (see section 4.5). 
Zaradi neznanega mehanizma nastanka nevtropenije, ki jo povzroči deferipron, bolniki ne smejo jemati zdravil, povezanih z nevtropenijo, ali takšnih, ki lahko povzročijo agranulocitozo (glejte poglavje 4.3).
This medicinal product contains less than 1 mmol sodium (23 mg) per tablet and that is to say essentially ‘sodium-free'. 
Zdravilo Deferiprone Lipomed vsebuje natrij To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na tableto, kar v bistvu pomeni, da je „brez natrija“.
Important Safety Reminders for Patients Taking Deferiprone Lipomed Prescribing doctor:________________________ Phone no:_______________________________ 
Pomembna varnostna opozorila za bolnike, ki jemljejo zdravilo Deferiprone Lipomed Zdravnik, ki je izdal recept:
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 500 mg deferiprone. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena filmsko obložena tableta vsebuje 500 mg deferiprona.
Dose adjustment is not required in patients with mild, moderate, or severe renal impairment (see section 5.2). 
Pri bolnikih z blago, zmerno ali hudo okvaro ledvic prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
NAME OF THE MARKETING AUTHORISATION HOLDER Lipomed GmbH 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Lipomed GmbH
Please refer to the patient/carer reminder card provided in the folding box. 
Glejte opozorilno kartico za bolnika/skrbnika, priloženo temu zložljivemu pakiranju.
Based on the results of this study, no adjustment of the deferiprone dosage regimen is required in patients with mildly or moderately impaired hepatic function. 
Na podlagi rezultatov te študije pri bolnikih z blago ali zmerno okvarjenim delovanjem jeter prilagoditev režima odmerjanja deferiprona ni potrebna.
See tables below for recommended doses for body weights at 10 kg increments. 
Priporočljive odmerke za telesne mase na vsakih 10 kg najdete v spodnjih preglednicah.
Deferiprone Lipomed 500 mg film-coated tablets deferiprone 
Deferiprone Lipomed 500 mg filmsko obložene tablete deferipron
Do not take aluminium-based antacids at the same time as taking Deferiprone Lipomed. 
Sočasno z zdravilom Deferiprone Lipomed ne jemljite antacidov na osnovi aluminija.
Please consult with your doctor or pharmacist before taking vitamin C with Deferiprone Lipomed. 
Pred jemanjem vitamina C ob zdravilu Deferiprone Lipomed se posvetujte z zdravnikom ali farmacevtom.
How to take Deferiprone Lipomed 
Kako jemati zdravilo Deferiprone Lipomed
Deferiprone Lipomed can be taken with or without food; however, you may find it easier to remember to take Deferiprone Lipomed if you take it with your meals. 
Zdravilo Deferiprone Lipomed se boste morda lažje spomnili vzeti, če ga boste jemali ob obrokih.
NAME OF THE MEDICINAL PRODUCT Deferiprone Lipomed 500 mg film-coated tablets 
IME ZDRAVILA Deferiprone Lipomed 500 mg filmsko obložene tablete
There are no data available on the use of deferiprone in patients with end stage renal disease or severe hepatic impairment (see section 5.2). 
Bolniki z motnjami v delovanju jeter oziroma ledvic in fibrozo jeter O uporabi deferiprona pri bolnikih s končno ledvično odpovedjo ali hudo jetrno okvaro podatki niso na voljo (glejte poglavje 5.2).
What Deferiprone Lipomed contains The active substance is deferiprone. 
Kaj vsebuje zdravilo Deferiprone Lipomed Učinkovina je deferipron.
Dose table for Deferiprone Lipomed 500 mg film-coated tablets Body weight (kg) 
Preglednica odmerkov za filmsko obložene tablete Deferiprone Lipomed 500 mg Telesna masa (kg)
Name and address of the manufacturer(s) responsible for batch release 
Ime in naslov izdelovalca, odgovornega za sproščanje serije Lipomed GmbH
White to off-white, glossy surface, oval film-coated tablet. 
Bele do sivobele, gladke ovalne filmsko obložene tablete.
Episodes of hypotonia, instability, inability to walk, and hypertonia with inability of limb movement have been reported in children in the post-marketing setting with standard doses of deferiprone. 
V obdobju trženja zdravila so pri otrocih, ki so prejemali standardne odmerke deferiprona, poročali o epizodah hipotonije, nestabilnosti, nezmožnosti za hojo in hipertonije z nezmožnostjo gibanja udov.
Talk to your doctor or pharmacist before taking Deferiprone Lipomed. 
Pred začetkom jemanja zdravila Deferiprone Lipomed se posvetujte z zdravnikom ali farmacevtom.
Do not take Deferiprone Lipomed if you are breast-feeding. 
Ne jemljite zdravila Deferiprone Lipomed, če dojite.
How to store Deferiprone Lipomed 
Shranjevanje zdravila Deferiprone Lipomed
Obtain a complete blood cell (CBC) count, with a white blood cell (WBC) count, corrected for the presence of nucleated red blood cells, a neutrophil count, and a platelet count immediately upon diagnosing the event and then repeat daily. 
Nemudoma po diagnozi nevtropenije izvedite preiskavo kompletne krvne slike s številom belih krvničk, korigiranim za nukleirane eritrocite, številom nevtrofilcev in trombocitov.
The safety and pharmacokinetics of Deferiprone Lipomed in patients with severe hepatic impairment are unknown. 
Varnost in farmakokinetika zdravila Deferiprone Lipomed pri bolnikih s hudo jetrno okvaro nista znani.
It is recommended that following recovery from neutropenia, weekly CBC, WBC, neutrophil and platelet counts continue to be obtained for three consecutive weeks, to ensure that the patient recovers fully. 
Te preiskave ponavljajte vsak dan. Priporočljivo je, da se po okrevanju od nevtropenije opravljajo tedenske preiskave kompletne krvne slike, števila belih krvničk, nevtrofilcev in trombocitov tri tedne zaporedoma.
In post-marketing experience with deferiprone, neurological disorders (such as tremors, walking disorders, double vision, involuntary muscle contractions, problems with movement coordination) have been reported in children who had been voluntarily prescribed more than double the maximum recommended dose of 100 mg/kg/day for several years. 
V obdobju trženja zdravila so pri otrocih, ki so prostovoljno nekaj let prejemali več kot dvakraten največji priporočeni odmerek 100 mg/kg/dan, poročali o nevroloških motnjah (kot so tremor, motnje pri hoji, dvojni vid, neželeno krčenje mišic in težave s koordinacijo gibanja).
The safety and pharmacokinetics of deferiprone in patients with severe hepatic impairment is unknown. 
Varnost in farmakokinetika deferiprona pri bolnikih s hudo jetrno okvaro nista znani.
The safety and pharmacokinetics of Deferiprone Lipomed in patients with end stage renal disease are unknown. 
Varnost in farmakokinetika zdravila Deferiprone Lipomed pri bolnikih s končno ledvično odpovedjo nista znani.
Do not take Deferiprone Lipomed: - if you are allergic to deferiprone or any of the other ingredients of this medicine (listed in section 6); - if you have a history of repeated episodes of neutropenia (low white blood cell (neutrophil) 
− če ste kdaj imeli ponavljajoče se epizode nevtropenije (znižana koncentracija belih krvničk
What Deferiprone Lipomed is and what it is used for Deferiprone Lipomed contains the active substance deferiprone. 
Kaj je zdravilo Deferiprone Lipomed in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Deferiprone Lipomed Kako jemati zdravilo Deferiprone Lipomed Možni neželeni učinki
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 500 mg deferiprone. 
NAVEDBA ENE ALI VEČ UČINKOVIN Ena filmsko obložena tableta vsebuje 500 mg deferiprona.
Increased appetite 
Presnovne in prehranske motnje povečan apetit
Macrogol 6000 
Obloga hipromeloza makrogol 6000 titanov dioksid
The safety and pharmacokinetics of deferiprone in patients with end stage renal disease is unknown. 
Varnost in farmakokinetika deferiprona pri bolnikih s končno ledvično odpovedjo nista znani.
One pack contains 100 film-coated tablets. 
Deferiprone Lipomed je na voljo v pretisnih omotih po 100 filmsko obloženih tablet.
Report immediately to your doctor any symptoms of infection such as fever, sore throat or flu-like symptoms. 
2. o kakršnih koli simptomih okužbe, kot so zvišana telesna temperatura, boleče grlo ali gripi podobni simptomi, takoj obvestili svojega zdravnika.
Neutropenia Agranulocytosis 
PRETISNI OMOTI
If you forget to take Deferiprone Lipomed 
Ne jemljite zdravila Deferiprone Lipomed
• you have cancer 
• imate raka.
• do not eat anything 
• ničesar ne jejte;
• For the next hour (60 minutes) after you've taken your tablet 
• Naslednjo uro (60 minut) potem, ko ste vzeli svojo tableto:
You can drink water but no other drinks 
Lahko pijete vodo, drugih pijač pa ne.
• If you can't stand or sit upright for at least one hour (60 minutes) at a time. 
• Če ne morete stati ali pokončno sedeti vsaj eno uro (60 minut) skupaj.
• before you have anything to eat or drink (on an empty stomach) 
• preden kar koli pojeste ali popijete (na prazen želodec).
• If your kidneys are not functioning normally. 
• če vaše ledvice ne delujejo normalno,
Choose one day of the month that will be easy to remember: 
Izberite en dan v mesecu, ki si ga boste najlaže zapomnili:
• serious, potentially life-threatening allergic reaction 
• resna, možno življenjsko ogrožujoča alergična reakcija;
• serious, potentially life-threatening allergic reaction (see section 2). 
• resna, možno življenjsko ogrožujoča alergična reakcija (glejte poglavje 2);
INFORMATION FOR THE HEALTHCARE PROFESSIONALS 
INFORMACIJE ZA ZDRAVSTVENO OSEBJE
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minisation) milestone being reached. 
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
• do not drink anything (except water if you need it) 
• ničesar ne pijte (razen vode, če jo potrebujete); • ne jemljite drugih zdravil.
Please see the Summary of Product Characteristics for more information. 
Prosimo, glejte Povzetek glavnih značilnosti zdravila za več informacij.
• If you have heart problems and the doctor recommended to limit your daily fluid intake. 
• Če imate težave s srcem in vam je zdravnik omejil dnevni vnos tekočine.
• Take your Bonviva tablet at least 6 hours after you last had anything to eat or drink except water. 
• Vzemite tableto zdravila Bonviva vsaj 6 ur po tem, ko ste zadnjič kar koli pojedli ali pili kar koli razen vode.
Bonviva is less effective if it's taken with food. 
Zdravilo Bonviva je manj učinkovito, če ga jemljete skupaj s hrano.
• Swallow your tablet with a full glass of water (at least 180 ml). 
• Tableto pogoltnite s polnim kozarcem vode (ne manj kot 180 ml).
• do not lie down; if you do not stay upright (standing or sitting), some of the medicine could leak back into your oesophagus 
• se ne ulezite; če ne ostanete v pokončnem položaju (stoje ali sede), lahko nekaj zdravila zaide nazaj v vaš požiralnik;
Bonviva It's important to keep taking Bonviva every month. 
Bonviva Pomembno je, da nadaljujete mesečno jemanje Bonvive.
If you develop these symptoms, stop taking Bonviva and tell your doctor straight away (see section 3). 
Če se pri vas pojavijo ti simptomi, prenehajte jemati zdravilo Bonviva in takoj obvestite svojega zdravnika (glejte poglavje 3).
Bonviva can treat osteoporosis only for as long as you keep receiving the treatment, even though you will not be able to see or feel a difference. 
Zdravilo Bonviva lahko zdravi osteoporozo le, dokler nadaljujete z uporabo zdravila, čeprav ne boste videli ali čutili razlike.
• Choose one day of the month that will be easy to remember. 
• Izberite si dan v mesecu, ki si ga boste lahko zapomnili.
You can choose either the same date (such as the 1st of each month) or the same day (such as the first Sunday of each month) to take your Bonviva tablet. 
Lahko izberete ali isti datum (npr. 1. v mesecu) ali isti dan (npr. prvo nedeljo v mesecu) za jemanje tablet zdravila Bonviva.
• or the same day (such as the first Sunday of each month). 
• ali isti dan (npr. prvo nedeljo v mesecu).
The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of Bonviva on an individual patient basis, particularly after 5 or more years of use. 
Potrebo po nadaljevanju zdravljenja z zdravilom Bonviva je treba periodično ponovno oceniti glede na koristi in tveganja za posameznega bolnika, še posebno po 5 letih ali več uporabe.
What Bonviva is and what it is used for 
Kaj je zdravilo Bonviva in za kaj ga uporabljamo
• After you've waited for an hour, you can have your first food and drink of the day. 
• Potem, ko ste počakali eno uro, lahko zaužijete svoj prvi dnevni obrok.
Bonviva belongs to a group of medicines called bisphosphonates. 
Bonviva spada v skupino zdravil, ki jih imenujemo difosfonati.
Method of administration For intravenous use over 15 - 30 seconds, every three months. 
Način uporabe Za intravensko uporabo v 15 do 30 sekundah, vsake tri mesece.
If you've taken more than one tablet by mistake, drink a full glass of milk and talk to your doctor straight away. 
Če ste vzeli večji odmerek zdravila Bonviva, kot bi smeli Če ste po pomoti vzeli več kot eno tableto, popijte poln kozarec mleka in se takoj posvetujte s svojim zdravnikom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 23 February 2004 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 23. februar 2004 Datum zadnjega podaljšanja:18. december 2013
Do not take Bonviva with food. 
Ne jemljite zdravila Bonviva skupaj s hrano.
• Supplements containing calcium, magnesium, iron or aluminium, as they could possibly influence the effects of Bonviva. 
• Dodatke, ki vsebujejo kalcij, magnezij, železo ali aluminij, ker imajo lahko vpliv na delovanje zdravila Bonviva.
Bonviva with food and drink: 
Zdravilo Bonviva skupaj s hrano in pijačo
Other medicines and Bonviva 
Druga zdravila in zdravilo Bonviva
Bonviva was not studied in the paediatric population, therefore no efficacy or safety data are available for this patient population. 
Zdravila Bonviva pri pediatričnih bolnikih niso proučevali, zato za to skupino bolnikov ni na voljo podatkov o učinkovitosti in varnosti.
INFORMATION IN BRAILLE Bonviva 150 mg 
PODATKI V BRAILLOVI PISAVI bonviva 150 mg
In case a dose is missed, patients should be instructed to take one Bonviva 150 mg tablet the morning after the tablet is remembered, unless the time to the next scheduled dose is within 7 days. 
Če bolnik odmerek izpusti, mu je treba svetovati, naj vzame eno 150-mg tableto zdravila Bonviva naslednje jutro potem, ko se spomni, razen če je do naslednjega načrtovanega odmerka manj kot 7 dni.
Children and adolescents Bonviva must not be used in children or adolescents below 18 years. 
Otroci in mladostniki Zdravila Bonviva se ne sme uporabljati pri otrocih ali mladostnikih, mlajših od 18 let.
Bonviva is prescribed to you to treat postmenopausal osteoporosis because you have an increased risk of fractures. 
Zdravilo Bonviva vam je zdravnik predpisal za zdravljenje pomenopavzne osteoporoze, ker imate povečano tveganje za zlome.
Talk to a nurse or doctor if any effects become troublesome or last more than a couple of days 
Obrnite se na medicinsko sestro ali zdravnika, če simptomi postanejo moteči ali trajajo več kot nekaj dni,
It's important to keep taking Bonviva every month, as long as your doctor prescribes it for you. 
Pomembno je, da vzamete zdravilo Bonviva vsak mesec, dokler vam ga je predpisal zdravnik.
• if you are allergic to ibandronic acid or any of the other ingredients of this medicine (listed in section 6) 
• če ste alergični na ibandronsko kislino ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Some patients need to be especially careful when using Bonviva. 
Nekateri bolniki morajo biti pri prejemanju zdravila Bonviva še posebno previdni.
Bonviva intravenous injection decreased levels of serum C-telopeptide of the alpha chain of Type I collagen (CTX) within 3 - 7 days of starting treatment and decreased levels of osteocalcin within 3 months. 
Intravenske injekcije zdravila Bonviva so zmanjšale vrednosti serumskih C-telopeptidov alfa verige kolagena tipa I (CTX) v 3 do 7 dneh po začetku zdravljenja in vrednosti osteokalcina v 3 mesecih.
Children and adolescents Do not give Bonviva to children or adolescents below 18 years. 
Otroci in mladostniki Zdravila Bonviva ne dajajte otrokom in mladostnikom, mlajšim od 18 let.
• If you forget to take your tablet on the morning of your chosen day, do not take a tablet later in the day. 
• Če ste pozabili vzeti tableto na jutro izbranega dne, ne vzemite tablete pozneje v istem dnevu.
Do not take Bonviva if you are pregnant or breast feeding. 
Ne jemljite zdravila Bonviva, če ste noseči ali dojite.
After swallowing your monthly Bonviva tablet, wait for 1 hour before taking any other medication, including indigestion tablets, calcium supplements, or vitamins. 
Vsak mesec, ko pogoltnete tableto zdravila Bonviva, počakajte 1 uro preden zaužijete katero koli drugo zdravilo, vključno z zdravili proti slabi prebavi, kalcijevimi dodatki ali vitamini.
After 5 years of using Bonviva, please consult with your doctor whether you should continue to take Bonviva. 
Po petih letih uporabe zdravila Bonviva se, prosimo, posvetujte z zdravnikom glede nadaljevanja jemanja zdravila Bonviva.
To get the most benefit from the treatment it is important to continue receiving the injections every 3 months for as long as your doctor prescribes it for you. 
Za najboljši izkoristek zdravljenja je pomembno, da nadaljujete s prejemanjem zdravila Bonviva vsake 3 mesece, dokler vam je zdravljenje predpisal zdravnik.
• either the same date (such as the 1st of each month) 
• ali isti datum (npr. 1. v mesecu),
Paediatric population (see section 4.2 and section 5.1) There are no data on the use of Bonviva in these age groups. 
Pediatrični bolniki (glejte poglavji 4.2 in 5.1) O uporabi zdravila Bonviva pri tej skupini bolnikov ni podatkov.
Irritation, inflammation or ulceration of the gullet/food pipe (oesophagus) often with symptoms of severe pain in the chest, severe pain after swallowing food and/or drink, severe nausea, or vomiting may occur, especially if you do not drink a full glass of water and/or if you lie down within an hour of taking Bonviva. 
Lahko pride do draženja, vnetja ali razjede požiralnika, pogosto s simptomi, kot so huda bolečina v prsih, huda bolečina pri požiranju hrane in/ali pitju pijače, huda slabost ali bruhanje, še posebej, če ne popijete polnega kozarca vode in/ali če se uležete prej kot v eni uri po zaužitju zdravila Bonviva.
Do not make yourself vomit, and do not lie down - this could cause Bonviva to irritate your oesophagus. 
Ne izzovite bruhanja in ne lezite - tako bi lahko zdravilo Bonviva dražilo vaš požiralnik.
In particular, products containing calcium, including milk, and other multivalent cations (such as aluminium, magnesium, iron), are likely to interfere with absorption of Bonviva, which is consistent with findings in animal studies. 
Posebno pripravki, ki vsebujejo kalcij, vključno z mlekom, in druge večvalentne katione (kot so aluminij, magnezij, železo) lahko vplivajo na absorpcijo zdravila Bonviva, kar je v skladu z ugotovitvami študij na živalih.
• Swallow your tablet whole, do not chew it, crush it or let it dissolve in your mouth. 
• Tableto pogoltnite celo - ne žvečite in ne prelamljajte tablete ter ne pustite, da se raztopi v ustih.
- Patients should not chew or suck the tablet, because of a potential for oropharyngeal ulceration 
- Bolniki tablet ne smejo žvečiti ali sesati, ker lahko pride do ulceracije žrela.
• Acetylsalicylic acid and other non-steroidal anti-inflammatory medicines (NSAIDs) (including ibuprofen, diclofenac sodium and naproxen) may irritate the stomach and intestine. 
• Acetilsalicilno kislino in druga nesteroidna protivnetna zdravila (NSAID, ki vključujejo ibuprofen, natrijev diklofenak in naproksen) lahko dražijo želodec in črevesje.